Skip to content

Replimune Group REPL Stock-Based Comp

Stock-Based Comp at other companies

Amgen logo
AmgenAMGN
$75M-11.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.65M+8.3%
Immunome logo
ImmunomeIMNM
$7.95M+39.5%
CG Oncology logo
CG OncologyCGON
$6.47M+25.7%
Erasca, Inc. logo
Erasca, Inc.ERAS
$8.46M+26.0%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's stock-based comp?
Replimune Group (REPL) reported stock-based comp of $7.05M in Q4 2025.
How has Replimune Group's stock-based comp changed year-over-year?
Replimune Group's stock-based comp decreased by 18.4% year-over-year, from $8.64M to $7.05M.
What is the long-term trend for Replimune Group's stock-based comp?
Over 3 years (2022 to 2025), Replimune Group's stock-based comp has grown at a 13.1% compound annual growth rate (CAGR), from $24.25M to $35.04M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.